Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $104.76, for a total value of $1,986,249.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Larry L. Wood also recently made the following trade(s):

  • On Friday, September 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $112.58, for a total value of $2,134,516.80.
  • On Wednesday, August 30th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $111.81, for a total value of $2,119,917.60.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at $107.09 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The company has a market capitalization of $22,660.00, a price-to-earnings ratio of 29.13, a P/E/G ratio of 1.88 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. During the same period last year, the business earned $0.68 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. research analysts predict that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/18/larry-l-wood-sells-18960-shares-of-edwards-lifesciences-corporation-ew-stock.html.

EW has been the subject of a number of research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $130.00 price objective (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Bank of America Corporation increased their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. Jefferies Group LLC increased their price objective on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. Canaccord Genuity reiterated a “buy” rating and issued a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, July 28th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $125.17.

Large investors have recently made changes to their positions in the business. ETF Managers Group LLC purchased a new position in Edwards Lifesciences Corporation in the second quarter worth about $112,000. Shine Investment Advisory Services Inc. purchased a new position in Edwards Lifesciences Corporation in the second quarter worth about $126,000. Cornerstone Advisors Inc. boosted its position in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after purchasing an additional 219 shares during the last quarter. Alexandria Capital LLC boosted its position in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after purchasing an additional 19 shares during the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new position in Edwards Lifesciences Corporation in the second quarter worth about $140,000. 82.17% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply